Analyst Rating: Will Editas Medicine Inc (EDIT) Stock Beat the Market?

Wednesday, March 13, 2024 12:02 PM | InvestorsObserver Analysts

Mentioned in this article

InvestorsObserver is giving Editas Medicine Inc (EDIT) an Analyst Rating Rank of 34, meaning EDIT is ranked higher by analysts than 34% of stocks. The average price target for EDIT is $15 and analyst’s rate the stock as a Buy.

Wall Street analysts are rating EDIT a Buy today. Find out what this means to you and get the rest of the rankings on EDIT!
See Full EDIT Report

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Editas Medicine Inc Stock Today?

Editas Medicine Inc (EDIT) stock is flat 0% while the S&P 500 is lower by -0.09% as of 12:02 PM on Wednesday, Mar 13. EDIT is unchanged $0.00 from the previous closing price of $8.61 on volume of 354,711 shares. Over the past year the S&P 500 has risen 31.93% while EDIT has gained 2.14%. EDIT lost -$2.02 per share the over the last 12 months. Click Here to get the full Stock Report for Editas Medicine Inc stock.

Share this article:

Related Articles